ReNeuron Group Plc has treated the first patient in a Phase 1 trial of a new stem-cell therapy that has been developed to treat patients left disabled by an ischaemic stroke. The trial is taking place in Glasgow, Scotland. ---Subscribe to MedNous to access this article--- Regenerative Medicine Company News
